Patents by Inventor Hsin-Ell Wang
Hsin-Ell Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10947270Abstract: The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.Type: GrantFiled: January 14, 2019Date of Patent: March 16, 2021Assignee: NATIONAL YANG-MING UNIVERSITYInventors: C. Allen Chang, Hsin-Ell Wang, Jia-Je Li, Shun-Fu Chang, Roy Chen-Chih Wu
-
Publication number: 20190211057Abstract: The present invention provides a targeted prodrug enzyme fusion carrier comprising a targeted molecule and a prodrug enzyme. The targeted prodrug enzyme fusion carrier can effectively identify and bind to tumor cells and tumor-induced tumor angiogenesis. The targeted prodrug enzyme fusion carrier also has a targeted prodrug enzyme fusion protein and a theranostic system utilizing the method of in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.Type: ApplicationFiled: January 14, 2019Publication date: July 11, 2019Inventors: C. Allen Chang, Hsin-Ell Wang, Jia-Je Li, Shun-Fu Chang, Roy Chen-Chih Wu
-
Patent number: 10202432Abstract: A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules (radiopharmaceuticals, isotopes, or chemotherapeutic drugs) or nanoparticles to form a conjugate.Type: GrantFiled: November 27, 2015Date of Patent: February 12, 2019Assignee: NATIONAL YANG-MING UNIVERSITYInventors: Cheng Allen Chang, Keng-Li Lan, Hsin-Ell Wang, Shun-Fu Chang, Jia-Je Li, Pei-Chia Chan
-
Patent number: 10117956Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.Type: GrantFiled: September 14, 2017Date of Patent: November 6, 2018Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUANInventors: Hsin-Ell Wang, Chien-Chung Hsia, Mao-Chi Weng, Kun-Liang Lin, Hao-Wen Kao, Chao-Cheng Chen, Kwan-Hwa Chi, Der-Chi Tien, Wuu-Jyh Lin
-
Publication number: 20180117188Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.Type: ApplicationFiled: September 14, 2017Publication date: May 3, 2018Inventors: Hsin-Ell WANG, Chien-Chung HSIA, Mao-Chi WENG, Kun-Liang LIN, Hao-Wen KAO, Chao-Cheng CHEN, Kwan-Hwa CHI, Der-Chi TIEN, Wuu-Jyh LIN
-
Patent number: 9789214Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.Type: GrantFiled: September 18, 2014Date of Patent: October 17, 2017Assignees: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, NATIONAL YANG-MING UNIVERSITYInventors: Hsin-Ell Wang, Chien-Chung Hsia, Mao-Chi Weng, Kun-Liang Lin, Hao-Wen Kao, Chao-Cheng Chen, Kwan-Hwa Chi, Der-Chi Tien, Wuu-Jyh Lin
-
Publication number: 20170058011Abstract: A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs.Type: ApplicationFiled: November 27, 2015Publication date: March 2, 2017Inventors: Cheng Allen CHANG, Keng-Li LAN, Hsin-Ell WANG, Shun-Fu CHANG, Jia-Je LI, Pei-Chia CHAN
-
Publication number: 20150231285Abstract: The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.Type: ApplicationFiled: September 18, 2014Publication date: August 20, 2015Inventors: Hsin-Ell WANG, Chien-Chung HSIA, Mao-Chi WENG, Kun-Liang LIN, Hao-Wen KAO, Chao-Cheng CHEN, Kwan-Hwa CHI, Der-Chi TIEN, Wuu-Jyh LIN
-
Patent number: 8961931Abstract: A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.Type: GrantFiled: April 7, 2011Date of Patent: February 24, 2015Assignee: Institute of Nuclear Energy Research, Atomic Energy CouncilInventors: Ting-Shien Duh, Wuu-Jyh Lin, Jenn-Tzong Chen, Li-Yuan Huang, Hsin-Ell Wang, Chuan-Lin Chen, Wen-Yi Chang, Hao-Wen Kao
-
Publication number: 20140221639Abstract: A radiolabeled nucleoside analogue is provided, which includes radioactive iodine 123I/131I, and a nucleoside analogue selected from a group consisting of cytidine, thymidine, uridine, and a derivative thereof. A method for preparing the radiolabeled nucleoside analogue, and a use thereof are further provided. The nucleoside analogue, prepared through the preparation method with a short synthesis time and a high radiochemical yield, has a long in vivo physiological half life and a high stability in serum, and, as a radiopharmaceutical composition, is useful in development of tumor proliferation diagnosis or therapy prognosis evaluation, and further assists in observation of long-time in vivo metabolism of a drug.Type: ApplicationFiled: April 8, 2014Publication date: August 7, 2014Applicants: Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan, NATIONAL YANG-MING UNIVERSITYInventors: HSIN-ELL WANG, CHIH-YUAN LIN, WEI-TI KUO, CHUAN-LIN CHEN, MEI-HUI WANG, HUNG-MAN YU, MAO-CHI WENG, YU CHANG, WUU-JYH LIN
-
Publication number: 20120259102Abstract: A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.Type: ApplicationFiled: April 7, 2011Publication date: October 11, 2012Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: Ting-Shien Duh, Wuu-Jyh Lin, Jenn-Tzong Chen, Li-Yuan Huang, Hsin-Ell Wang, Chuan-Lin Chen, Wen-Yi Chang, Hao-Wen Kao
-
Publication number: 20120178919Abstract: A radiolabeled nucleoside analogue is provided, which includes radioactive iodine 123I/131I, and a nucleoside analogue selected from a group consisting of cytidine, thymidine, uridine, and a derivative thereof. A method for preparing the radiolabeled nucleoside analogue, and a use thereof are further provided. The nucleoside analogue, prepared through the preparation method with a short synthesis time and a high radiochemical yield, has a long in vivo physiological half life and a high stability in serum, and, as a radiopharmaceutical composition, is useful in development of tumor proliferation diagnosis or therapy prognosis evaluation, and further assists in observation of long-time in vivo metabolism of a drug.Type: ApplicationFiled: July 29, 2011Publication date: July 12, 2012Applicants: NATIONAL YANG-MING UNIVERSITY, Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: HSIN-ELL WANG, CHIH-YUAN LIN, WEI-TI KUO, CHUAN-LIN CHEN, MEI-HUI WANG, HUNG-MAN YU, MAO-CHI WENG, YU CHANG, WUU-JYH LIN
-
Publication number: 20090081121Abstract: The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject.Type: ApplicationFiled: September 25, 2008Publication date: March 26, 2009Applicants: National Health Research Institute, National Yang Ming University, Taiwan Liposome Company, Ltd.Inventors: Gann Ting, Yun-Long Tseng, Jun-Jen Liu, Hsin-Ell Wang, Jeng-Jong Hwang, Yi-Ching Lu, Wan-Chi Lee
-
Publication number: 20070154390Abstract: A nuclear molecular imaging contrast agent. The nuclear imaging contrast agent comprises a polymer according to the structure of wherein, P is and 1 is not less than 1; D is a C3-30 dendritic moiety having a plurality of oxygen residue; Z is a C3-20 moiety having a plurality of functional groups, wherein the functional groups comprise carbonyl, carboxyl, amine, ester, amide, or chelate group; L is a radioisotope or analyte-specific moiety ; m is not less than two ; and at least one X is an analyte-specific moiety; the other X can be hydrogen atom.Type: ApplicationFiled: June 9, 2006Publication date: July 5, 2007Inventors: Huang Chien Liang, Hsin-Ell Wang, Chin-I Lin, Shian-Jy Wang